August 2nd, 2022 | 10:57 CEST
Defence Therapeutics VP Research + Development Dr. Moutih Rafei on the next generation oncology-targeting therapies
Table of contents:
"[...] We are working closely with the University of Miami's Department of Psychology. [...]" Evan Levine, CEO, PsyBio Therapeutics
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Cancer is one of the most common causes of death and those affected often have a long journey of suffering. What progress can Defence Therapeutics show in the field of fighting the disease?
'Cancer is a multifactorial disease caused by mutations accumulated through years. Therefore, targeting cancer through a specific pathway may not lead to the hoped-for outcome.
Defence is working on the development of the next generation oncology-targeting therapies. Most of its arsenal is based on the use of the Accum technology, which consists of empowering biomedicine's accumulation into target cells via endosomal escape.
As such, the company has developed antibody-drug conjugates, anti-cancer small molecules and protein- or cell-based anti-cancer vaccine formulations. Multiple Phase I trials using some of these products are expected to start in Q1/Q2 of 2023.'
Dr. Moutih Rafei, VP Research & Development, Defence Therapeutics Inc.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.